Skip to main content

Estimation of the cancer risk to humans resulting from the presence of cyclophosphamide and ifosfamide in surface water

Environmental Science and Pollution Research volume 17, pages 486–496 (2010)Cite this article

Abstract

Background, aim, and scope

Anti-tumour agents and their metabolites are largely excreted into effluent, along with other pharmaceuticals. In the past, investigations have focused on the input and analysis of pharmaceuticals in surface and ground water. The two oxazaphosphorine compounds, cyclophosphamide and ifosfamide are important cytostatic drugs used in the chemotherapy of cancer and in the treatment of autoimmune diseases. Their mechanism of action, involving metabolic activation and unspecific alkylation of nucleophilic compounds, accounts for genotoxic and carcinogenic effects described in the literature and is reason for environmental concern. The anti-tumour agents cyclophosphamide (CP) and ifosfamide (IF) were not biodegraded in biodegradation tests. They were not eliminated in municipal sewage treatment plants. Degradation by photochemically formed HO radicals may be of some relevance only in shallow, clear, and nitrate-rich water bodies but could be further exploited for elimination of these compounds by advanced oxidation processes, i.e. in a treatment of hospital waste water. Therefore, CP and IF are assumed to persist in the aquatic environment and to enter drinking water via surface water. The risk to humans from input of CP and IF into surface water is not known.

Materials and methods

The local and regional, i.e. nationwide predicted environmental concentration (PEClocal, PECregional) of CP and IF was calculated for German surface water. Both compounds were measured in hospital effluents, and in the influent and effluent of a municipal treatment plant. Additionally, published concentrations in the effluent of sewage treatment plants and surface water were used for risk assessment. Excretion rates were taken into account. For a worst-case scenario, maximum possible ingestion of CP or IF by drinking 2 L a day of unprocessed surface water over a life span of 70 years was calculated for adults. Elimination in drinking water processing was neglected, as no data is available. This intake was compared with intake during anti-cancer treatment.

Results and discussion

Intake of CP and IF for anti-cancer treatment is typically 10 g within a few months. Under such conditions, a relative risk of 1.5 for the carcinogenic compounds CP and IF is reported in the literature. In the worst case, the maximum possible intake by drinking water is less than 10−3 (IF) and 10−5 (CP) of this amount, based on highest measured local concentrations. On a nationwide average, the factor is approx. 10−6 or less.

Conclusions

The additional intake of CP and IF due to their emission into surface water and its use without further treatment as drinking water is low compared to intake within a therapy. This approach has shortcomings. It illustrates the current lack of methodology and knowledge for the specific risk assessment of carcinogenic pharmaceuticals in the aquatic environment. IF and CP are directly reacting with the DNA. Therefore, with respect to health effects a safe threshold concentration for these compounds cannot be given. The resulting risk is higher for newborns and children than for adults. Due to the lack of data the risk for newborns and children cannot be assessed fully. The data presented here show that according to present knowledge the additional risk of cancer cannot be fully excluded, especially with respect to children. Due to the shortage of data for effects of CP and IF in low doses during a whole lifespan, possible effects were assessed using data of high doses of CP and IF within short-term ingestion, i.e. therapy. This remains an unresolved issue. Anyway, the risk assessment performed here could give a rough measure of the risks on the one hand and the methodological shortcomings on the other hand which are connected to the assessment of the input of genotoxic and carcinogenic pharmaceuticals such as CP and IF into the aquatic environment. Therefore, we recommend to take measures to reduce the input of CP and IF and other carcinogenic pharmaceuticals. We hope that our manuscript further stimulates the discussion about the human risk assessment for carcinogenic pharmaceuticals in the aquatic environment.

Recommendations and perspectives

CP and IF are carcinogens. With respect to newborn and children, reduction of the emission of CP and IF into effluent and surface water is recommended at least as a precautionary measure. The collection of unused and outdated drugs is a suitable measure. Collection of patients’ excreta as a measure of input reduction is not recommended. Data suitable for the assessment of the risk for newborn and children should be collected in order to perform a risk assessment for these groups. This can stimulate discussion and give new insights into risk assessment for pharmaceuticals in the environment. Our study showed that in the long term, effective risk management for the reduction of the input of CP and IF are recommendable.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  • Allwood M, Wright P (1993) The cytotoxics handbook. 2nd edn. Oxford Radcliffe

  • ASTA Medica AG (1992) Information for users of cyclophosphamide and ifosfamide. Frankfurt

  • Bagley CM Jr, Bostick FW, De Vita VT Jr (1973) Clinical pharmacology of cyclophosphamide. Cancer Res 33:226–233

    Google Scholar 

  • Bier V, Jürgens H, Etspüler G et al (1987) 120-h continuous infusion of ifosfamide alone and in combination with cis-platinum in children and adolescents with recurrent Ewing’s sarcoma. Contr Oncol 26:131–138

    Google Scholar 

  • Boos J, Welslau U, Ritter J et al (1991) Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemoth Pharm 28:455–460

    Article  CAS  Google Scholar 

  • Boos J, Welslau U, Ritter J, Blaschke G, Schellong G (1992) Ifosfamide and its ‘side chain oxidized’ metabolites—urinary excretion under different pediatric treatment schedules. Klin Pädiatr 204:299–305

    Article  CAS  Google Scholar 

  • Brock N, Pohl J (1987) The basis of modern ifosfamide therapy. Contrib Oncol 26:1–11

    Google Scholar 

  • Buerge IJ, Buser HR, Poiger T, Müller MD (2006) Occurrence and fate of the cytostatic drugs cyclophosphamide and ifosfamide in wastewater and surface waters. Environ Sci Technol 40:7242–7250

    Article  CAS  Google Scholar 

  • Christensen FM (1998) Pharmaceuticals in the environment—a human risk? Regul Toxicol Pharm 28:212–221

    Article  CAS  Google Scholar 

  • Clever LH, Omenn GS (1988) Hazards for health care workers. Annu Rev Publ Health 9:273–303

    Article  CAS  Google Scholar 

  • Clewell HJ, Gentry PR, Gearhart JM, Allen BC, Andersen ME (1995) Considering pharmacokinetic and mechanistic information in cancer risk assessment for environmental contaminants: examples with vinylchloride and trichloroethylene. Chemosphere 31:2561–2578

    Article  CAS  Google Scholar 

  • Cooke J, Williams J, Morgan RJ, Cooke P, Calvert RT (1991) Use of cytogenetic methods to determine mutagenic changes in the blood of pharmacy personnel and nurses who handle cytotoxic agents. Am J Hosp Pharm 48:1199–1205

    CAS  Google Scholar 

  • Dieter HH, Mückter H (2007) Assessment of so called organic trace compounds in drinking water from the regulatory, health and aesthetic-quality points of view, with special consideration given to pharmaceuticals. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 50:322–331

    Article  CAS  Google Scholar 

  • Ensslin AS, Stoll Y, Pethran A, Pfaller A, Römmelt R, Fruhmann G (1994) Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med 51:229–233

    Article  CAS  Google Scholar 

  • European Environment Agency, WHO Regional Office for Europe (2002) Children’s health and environment: a review of evidence. Environmental issue report No 29, EEA, Copenhagen, 2002

  • European Union, Direction General III (1995) Assessment of potential risks to the environment posed by medical products for human use (excluding products containing live genetically modified organisms. No. 5504/94 Draft 6, version 4, Brusse

  • Fichtner I, Nowak C (1987) Pharmacological and toxicological effects of ifosfamide (Haloxan®) combined with mesna (Uromitexan®) in different urine tumor models. Contrib Oncol 26:93–104

    Google Scholar 

  • Gilard V, Malet-Martino MC, De Forni M, Niemeyer U, Ader JC, Martino R (1993) Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosporous-31 nuclear magnetic resonance spectroscopy. Cancer Chemoth Pharm 31:387–394

    Article  CAS  Google Scholar 

  • Goren MP (1991) Determination of urinary 2- and 3-dechloroethylated metabolites of ifosfamide by high performance liquid chromatography. J Chromatogr - Biomed 570:351–360

    Article  CAS  Google Scholar 

  • Greene MH, Harris EIL, Gershenson DM, Malkasian GD, Melton LJ, Dembo AJ, Bennet JM, Moloney WC, Boice JC (1986) Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 105:360–367

    CAS  Google Scholar 

  • Grochow LB, Calvin M (1983) Clinical pharmacokinetics of cyclophosphamide. In: Ames MM, Povis GG, Kovach IS (eds) Pharmacokinetics of anticancer agents in humans. Elsevier, New York

    Google Scholar 

  • Haas JF, Kittelmann B, Mehnert WH, Staneczek W, Möhner M, Kaldor JM, Day NE (1987) Risk of leukemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Brit J Cancer 55:213–218

    CAS  Google Scholar 

  • Hansch C, Leao A, Hoekman D (1995) Exploring QSAR: Hydrophobic, electronic and stric conctants. American Chemical Society, Washington DC

    Google Scholar 

  • Heberer T (2002) Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicol Lett 131:5–17

    Article  CAS  Google Scholar 

  • International Agency for Research on Cancer (1975) Cyclophosphamide. IARC Monographs on the evaluation of the carcinogenic risk of chemicals. Lyon 9:135–156

    Google Scholar 

  • International Agency for Research on Cancer (1981) Cyclophosphamide. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals. Lyon 26:165–202

    Google Scholar 

  • Jjemba PK (2008) Pharmaecology. Wiley, Hoboken, NJ, p 105

    Google Scholar 

  • Kim S, Aga DS (2007) Potential ecological and human health impacts of antibiotics and antibiotic-resistant bacteria from waste water treatment plants. J Toxicol Env Heal B 10:559–573

    Article  CAS  Google Scholar 

  • Kinlen LJ (1985) Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 78:44–49

    Article  CAS  Google Scholar 

  • Kinlen LJ, Sheil AG, Peto J (1979) Collaborative United Kingdom–Australian study of cancer in patients treated with immunosuppressive drugs. Br Med J iv:1461–1466

  • Kinlen LJ, Peto J, Doll R, Sheil AG (1981) Cancer in patients treated with immunosuppressive drugs. Br Med J 282:474

    Article  CAS  Google Scholar 

  • Knight A, Asklin J, Granath F, Sparen P, Ekbom A (2004) Urinary bladder cancer in Wegener's granulomatosis: risk and relation to cyclophosphamide. Ann Rheum Dis 63:1307–1311

    Article  CAS  Google Scholar 

  • Kümmerer K (2007) Sustainable from the very beginning. Rational design of molecules by life cycle engineering as an important approach for green pharmacy and green chemistry. Green Chem 9:899–907

    Article  Google Scholar 

  • Kümmerer K (Ed.) (2008) Pharmaceuticals in the environment. Sources, fate, effects, and risk. 3rd ed. Springer, Heidelberg

  • Kümmerer K, Steger-Hartmann T, Baranyai A (1996) Evaluation of the biological degradation of the antineoplastics cyclophosphamide and ifosfamide with the closed bottle test (OECD 301 D). Zbl Hyg 198:215–225

    Google Scholar 

  • Kümmerer K, Steger-Hartmann T, Meyer M (1997) Biodegradability of the anti-tumour agent ifosfamide and its occurrence in sewage. Water Res 31:2705–2710

    Article  Google Scholar 

  • Kümmerer K, Al-Ahmad A, Bertram B, Wießler M (2000) Biodegradability of antineoplastic compounds in screening tests: improvement by glucosidation and influence of stereo-chemistry. Chemosphere 40:767–773

    Article  Google Scholar 

  • Martino R, Crasnier F, Chouini Lalanne N, Gilard V, Niemeyer U, de Forni M, Malet-Martino MC (1992) A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with phosporus-31 nuclear magnetic resonance spectroscopy. J Pharmacol Exp Ther 260:1133–1144

    CAS  Google Scholar 

  • Matney TS, Ngyuen TV, Connor TH, Ana WJ, Theiss JC (1985) Genotoxic classification of anti-cancer drugs. Teratogen Carcin Mut 5:319–328

    Article  CAS  Google Scholar 

  • Momerency G, Van Cauwenberghe K, De Bruijn EA, Van Oosterom AT, Highley MS, Harper PG (1994a) Determination of ifosfamide and seven metabolites in blood plasma, as stable trifluoracetyl derivatives, by electron capture chemical ionization GC-MS. J High Res Chromatog 17:655–661

    Article  CAS  Google Scholar 

  • Momerency G, Van Cauwenberghe K, Slee PH, Van Oosterom AT, De Bruijn EA (1994b) The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoracetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry. Biol Mass Spectrom 23:149–158

    Article  CAS  Google Scholar 

  • Pedersen-Bjergaard J, Ersboll J, Sorensen HM, Keiding N, Larsen SO, Philip P, Larsen MS, Schultz H, Nissen NI (1985) Risk of acute non-lymphocytic leukaemia and preleukaemia in patients treated with cyclophosphamide for non-Hodgkin’s lymphomas. Ann Intern Med 103:195–200

    CAS  Google Scholar 

  • Plotz PH, Kippel HJ, Decker JL, Grauman D, Wolff B, Brown BC, Rutt G (1979) Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 91:221–223

    CAS  Google Scholar 

  • Richardson ML, Bowron JM (1985) The fate of pharmaceutical chemicals in the aquatic environment. J Pharm Pharmacol 37:1–12

    CAS  Google Scholar 

  • Saul G, Matthias M, Rose H, Pradel I (1979) Excretion pattern of alkylating metabolites in urine following cyclophosphamide treatment of tumor patients: influence of application route, dosage, liver and kidney function. J Cancer Res Clin 94:277–286

    Article  CAS  Google Scholar 

  • Schecker J, Al-Ahmad A, Bauer MJ, Zellmann H, Kümmerer K (1998) Elimination des Zytostatikums Ifosfamid während der simulierten Zersetzung von Hausmüll im Labormaßstab. (Elimination of the cytotoxic ifosfamide during the simulation of household waste in laboratory scale) Umweltwiss Schadst Forsch 10:339–344

    CAS  Google Scholar 

  • Schulman LJ, Sargent EV, Naumann BD, Faria EC, Dolan DG, Wargo JP (2002) A human health risk assessment of pharmaceuticals in the aquatic environment. Hum Ecol Risk Assess 8:657–680

    Article  CAS  Google Scholar 

  • Schwab BW, Hayes EP, Fiori JM, Mastrocco FJ, Roden NM, Cragin D, Meyerhoff RD, D’Aco VJ, Anderson PD (2005) Human pharmaceuticals in US surface waters: a human health risk assessment. Regul Toxicol Pharm 42:296–312

    Article  CAS  Google Scholar 

  • Sessink PJM, Kroese ED, Van Kranen HJ, Bos RP (1995) Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occ Env Hea 67:317–323

    Article  CAS  Google Scholar 

  • Sorsa M, Pyy L, Salomaa S, Nylund L, Yager JW (1988) Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals. Mutat Res 204:465–479

    Article  CAS  Google Scholar 

  • Statistisches Bundesamt (German Federal Statistical Agency) (1990) Umweltschutz, Fachserie 19, Reihe 1.2 Abfallbeseitigung im Produzierenden Gewerbe. Metzler Pöschel, Wiesbaden (1994)

  • Steger-Hartmann T (1995) Thesis, University of Freiburg

  • Steger-Hartmann T, Kümmerer K, Schecker J (1996) Trace analysis of the anti-neoplastics ifosfamide and cyclophosphamide in sewage water by two step solid phase extraction and GC/MS. J Chromatogr A 726:179–184

    Article  CAS  Google Scholar 

  • Steger-Hartmann T, Kümmerer K, Hartmann A (1997) Biological degradation of cyclophosphamide and its occurrence in sewage water. Ecotox Environ Safe 36:174–179

    Article  CAS  Google Scholar 

  • Travis LB, Curtis RE, Stovall M, Holowaty EJ, van Leeuwen FE, Glimelius B, Lynch CF, Hagenbeek A, Li CY, Banks PM (1994) Risk of leukaemia following treatment for non-Hodgkin’s lymphoma. J Natl Cancer I 86:1450–1457

    Article  CAS  Google Scholar 

  • Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adam J, Gospodarowicz MK, Wacholder S, Inskip PD, Tucker MA, Boice JD (1995) Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J Natl Cancer I 87:524–530

    Article  CAS  Google Scholar 

  • Umweltbundesamt (2004) Umweltbedingte Gesundheitsrisisken—was ist bei Kindern anders als bei Erwachsenen? Berlin

  • Umweltbundesamt (2003) Bewertung der Anwesenheit teil- oder nicht bewertbarer Stoffe im Trinkwasser aus gesundheitlicher Sicht. (Recommendation of the Federal Environment Agency of March 2003 ‘Assessing the presence of substances in drinking water without (adequate) toxicological database from the health point of view’) Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 46:249–251

  • US EPA (2003) Adjusting for youth, update cancer risk guidelines. Environ Health Persp 111:A 708–710

    Google Scholar 

  • Wagner T, Ehinger G (1987) Self-induction of cyclophosphamide and ifosfamide metabolism by repeated high dose-treatment. Contrib Oncol 26:69–75

    Google Scholar 

  • Webb S, Ternes T, Gibert M, Olejniczak K (2003) Indirect human exposure to pharmaceuticals via drinking water. Toxicol Lett 142:157–167

    Article  CAS  Google Scholar 

  • Zuccato E, Calamari D, Natangeleo M, Fanelli R (2000) Presence of therapeutic drugs in the environment. Lancet 355:1789–1790

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to thank E. Strehl (Freiburg University Hospital Pharmacy) for providing the data on local use of cyclophosphamide and ifosfamide. Also, B. Dries (Abwasserzweckverband Breisgauer Bucht) for sampling the influent and effluent of the sewage treatment plant and A. Eitel for GC/MS-analysis. The work presented was supported by the "Projekt Wasser-Abfall-Boden (PWAB)” of the Ministry of Environment of Baden-Württemberg (Grant PA 94 154).

Author information

Author notes

  1. Ali Al-Ahmad

    Present address: Department of Preservative Dentistry and Periodontology, University Medical Centre Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany

Affiliations

  1. Department of Environmental Health Sciences, University Medical Centre Freiburg, Breisacherstraße 115b, 79106, Freiburg, Germany

    Klaus Kümmerer

Authors
  1. Klaus Kümmerer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ali Al-Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Kümmerer.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kümmerer, K., Al-Ahmad, A. Estimation of the cancer risk to humans resulting from the presence of cyclophosphamide and ifosfamide in surface water. Environ Sci Pollut Res 17, 486–496 (2010). https://doi.org/10.1007/s11356-009-0195-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11356-009-0195-4

Keywords

  • Cancer
  • Cyclophosphamide
  • Drinking water
  • Excretion
  • Hospital effluent
  • Ifosfamide
  • Intake
  • Life span
  • Risk
  • Surface water